Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: improbable (1), doubtful (8), not likely (447)

Lenalidomide-Rituximab IV

Description: Chemotherapy Protocol LYMPHOMA LENALIDOMIDE-RITUXIMAB (IV) There are multiple versions of this protocol in use. Please ensure you have the correct p
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Lenalidomide-Rituximab-IV.pdf

Pembrolizumab_400mg (lymphoma)

Description: Chemotherapy Protocol LYMPHOMA Pembrolizumab (400mg) Regimen • Lymphoma – Pembrolizumab (400mg) Indication • Pembrolizumab is indicated for
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Pembrolizumab-400mg.pdf

Pembrolizumab_200mg (lymphoma)

Description: Chemotherapy Protocol LYMPHOMA Pembrolizumab (200mg) Regimen • Lymphoma – Pembrolizumab (200mg) Indication • Pembrolizumab is indicated for
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Pembrolizumab-200mg.pdf

Nivolumab (lymphoma)

Description: Chemotherapy Protocol LYMPHOMA Nivolumab Regimen • Lymphoma – Nivolumab Indication • Nivolumab is recommended as an option for treating relapse
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Nivolumab.pdf

Nivolumab 240mg (lymphoma)

Description: Chemotherapy Protocol LYMPHOMA Nivolumab (240mg-14 days) Regimen • Lymphoma – Nivolumab (240mg-14 days) Indication • Nivolumab is recommended as an option f
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Nivolumab-240mg.pdf

InP-REPOCH-Cyclophosphamide-Doxorubicin-Etoposide-Prednisolone-Rituximab-Vincristine

Description: Chemotherapy Protocol LYMPHOMA REPOCH - CYCLOPHOSPHAMIDE-DOXORUBICIN-ETOPOSIDE-PREDNISOLONERITUXIMAB-VINCRISTINE (In-Patient Dose adjusted regime
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/InP-REPOCH.pdf

InP-MATRix

Description: Chemotherapy Protocol LYMPHOMA MATRix – CYTARABINE-METHOTREXATE-RITUXIMAB-THIOTEPA Inpatient Regimen Regimen • Lymphoma – InP-MATRix – Cytarabin
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/InP-MATRix.pdf

InP RIVAC (66) cytarabine etoposide ifosfamide rituximab

Description: Chemotherapy Protocol LYMPHOMA CYTARABINE-ETOPOSIDE-IFOSFAMIDE-RITUXIMAB (RIVAC) 66 years and above Inpatient Regimen There ar
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/InP-RIVAC-66-cytarabine-etoposide-ifosfamide-rituximab.pdf

InP RIVAC (65) cytarabine etoposide ifosfamide rituximab

Description: Chemotherapy Protocol LYMPHOMA CYTARABINE-ETOPOSIDE-IFOSFAMIDE-RITUXIMAB (RIVAC) 65 years and below Inpatient Regimen There ar
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/InP-RIVAC-65-cytarabine-etoposide-ifosfamide-rituximab.pdf

InP methotrexate

Description: Chemotherapy Protocol LYMPHOMA METHOTREXATE Inpatient Regimen Regimen • Lymphoma – InP-Methotrexate Indication • Non-Hodgkin’s Lymphoma (NHL), i
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/InP-methotrexate.pdf

321 to 330 of 494

Previous … 31 32 33 34 35 … Next